| Literature DB >> 27992525 |
Iftach Sagy1,2,3, Alina Vodonos1,3, Victor Novack1,2,3, Boris Rogachev2,3,4, Yosef S Haviv2,3,4, Leonid Barski2,3.
Abstract
BACKGROUND: The aging kidney manifests structural, functional as well as pharmacological changes, rendering elderly patients more susceptible to adverse environmental influences on their health, dehydration in particular. HYPOTHESIS: Higher temperature is associated with renal function impairment in patients 65 years and older who routinely take thiazide and/or ACE-inhibitors/ARBs.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27992525 PMCID: PMC5167394 DOI: 10.1371/journal.pone.0168504
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow chart of four medication groups.
Baseline demographic and clinical characteristics of patients according to type of treatment on hospital admission.
| None(n = 13,418) | ACE/ARBs (1)(n = 6,697) | thiazide (2)(n = 2,680) | ACE/ARBs+ thiazide (3)(n = 3,491) | P value | ||
|---|---|---|---|---|---|---|
| Demographic Characteristics | Male gender, n(%) | 7,431 (55.4) | 3,665 (54.7) | 1,306 (48.7) | 1,806 (51.2) | <0.001 |
| Age (years), mean ±SD | 75.7 (±6.8) | 75.5 (±6.7) | 76.5 (±6.8) | 76.2 (±6.7) | <0.001 | |
| Systolic blood pressure(mmHg), mean ±SD | 138.9 (±51.9) | 141.9 (±42.3) | 137.6 (±38.9) | 141.5 (±52.8) | <0.001 | |
| Diastolic blood pressure (mmHg), mean ±SD | 74.9 (±21.9) | 76.1 (±29.7) | 74.2 (±19.3) | 74.3 (±19.5) | <0.001 | |
| Mean arterial blood pressure (mmHg), mean ±SD | 96.2 (±22.8) | 98.0 (±25.2) | 95.3 (±19.6) | 96.7 (±22.4) | <0.001 | |
| NewMyocardial infarction, n(%) | 811 (6.0%) | 433 (6.5%) | 148 (5.5%) | 192 (5.5%) | 0.155 | |
| Heart failure,n(%) | 672 (5.0%) | 308 (4.6%) | 511 (19.1%) | 620 (17.8%) | <0.001 | |
| Diabetes Mellitus, n(%) | 3,647 (27.2) | 2,582 (38.7) | 899 (33.6) | 1,371 (39.4) | <0.001 | |
| Peripheral vascular disease, n(%) | 350 (2.6%) | 177 (2.6%) | 88 (3.3%) | 122 (3.5%) | 0.012 | |
| Stroke, n(%) | 827 (6.2%) | 565 (8.5%) | 187 (7.0%) | 280 (8.0%) | <0.001 | |
| Liver disease, n(%) | 307 (2.3%) | 48 (0.7%) | 100 (3.7%) | 27 (0.8%) | <0.001 | |
| Dementia, n(%) | 571 (4.3%) | 202(3.0%) | 75 (2.8%) | 74 (2.1%) | <0.001 | |
| Cancer, n(%) | 223 (1.7%) | 104 (1.6%) | 41 (1.5%) | 45 (1.3%) | 0.450 | |
| Infection, n(%) | 667 (5.0%) | 290 (4.3%) | 94 (3.5%) | 131 (3.8%) | <0.001 | |
| Cardiovascular, n(%) | 5595 (41.7%) | 3227 (48.2%) | 1140 (42.5%) | 1679 (48.1%) | <0.001 | |
| Respiratory, n(%) | 2652 (19.8%) | 1199 (17.9%) | 622 (23.2%) | 720 (20.6%) | <0.001 | |
| Gastrointestinal, n(%) | 1271 (9.5%) | 501(7.5%) | 244(9.1%) | 216 (6.2%) | <0.001 | |
| Renal or dehydration, n(%) | 492 (3.7%) | 219 (3.3%) | 102 (3.8%) | 135 (3.9%) | 0.346 | |
| Other, n(%) | 2741 (20.4%) | 1261 (18.8%) | 478 (17.8%) | 610 (17.5%) | <0.001 |
ACE/ARBs—angiotensin-converting-enzyme inhibitor or angiotensin receptor blockers
Baseline laboratory characteristics of patients according to type of treatment on hospital admission.
| None(n = 13,418) | ACE/ARBs (1) (n = 6,697) | thiazide (2) (n = 2,680) | ACE/ARBs+ thiazide (3) (n = 3,491) | P value | |
|---|---|---|---|---|---|
| First creatinine (mg/dL) mean ±SD | 1.02±0.45 | 1.02±0.39 | 1.21±0.56 | 1.18±0.49 | <0.001 |
| Maximum Creatinine (mg/dL) mean ±SD | 1.13±0.58 | 1.12±0.50 | 1.37±0.76 | 1.33±0.65 | <0.001 |
| Last Creatinine (mg/dL) mean ±SD | 1.02±0.48 | 1.02±0.41 | 1.23±0.61 | 1.18±0.53 | <0.001 |
| Estimated GFR on admission (mL/min), mean ±SD | 80.7 (±24.7) | 82.2 (±23.2) | 72.1 (±27.2) | 75.0 (±25.5) | <0.001 |
| Urea (mg/dL) mean ±SD | 47.7 (±26.3) | 47.4 (±21.3) | 62.7 (±38.2) | 60.5 (±33.2) | <0.001 |
| Sodium (mEq/L), mean ±SD | 138.3 (±3.6) | 138.3 (±3.6) | 137.9 (±4.1) | 138.0 (±3.8) | <0.001 |
| Uric Acid (mg/dL) mean ±SD | 5.9 (±2.0) | 6.0 (±1.9) | 7.3 (±2.5) | 7.2 (±2.2) | <0.001 |
| Albumin (g/dl), mean ±SD | 3.7 (±0.5) | 3.8 (±0.5) | 3.7 (±0.5) | 3.7 (±0.5) | <0.001 |
| Stage 1 or no CKD | 4442(53.6%) | 2480 (54.2%) | 769 (45.7%) | 1119 (45.7%) | <0.001 |
| CKD Stage 2 | 2557 (30.9%) | 1470 (32.1%) | 573 (34.1%) | 829 (35.2%) | |
| CKD Stage 3 | 996 (12.0%) | 499 (10.9%) | 277 (16.5%) | 352 (14.9%) | |
| CKD Stage 4 | 207 (2.5%) | 95 (2.1%) | 54 (3.2%) | 41 (1.7%) | |
| CKD Stage 5 | 83 (1.0%) | 33 (0.7%) | 8 (0.5%) | 16 (0.7%) |
*Based on the mean creatinine in the preceding year prior to the admission which was available for 61.5% of study cohort
ACE/ARBs—angiotensin-converting-enzyme inhibitor or angiotensin receptor blockers, GFR–glomerular filtration rate
Baseline creatinine and estimates of the effect of daily temperature on renal function, by medication groups*.
| ALL SEASONS | Increase of5°C | ||||
|---|---|---|---|---|---|
| Treatment groups | Baseline Creatinine (ml/min) | % change in Creatinine | 95% CI for % change in Creatinine | P value | |
| None | 0.824 | 1.212 | 0.082 | 2.354 | 0.036 |
| ACE/ARBs | 0.895 | 1.147 | -0.218 | 2.530 | 0.100 |
| thiazide | 1.006 | 0.702 | -1.872 | 3.345 | 0.597 |
| ACE/ARBs and thiazide | 1.032 | 3.440 | 1.227 | 5.700 | 0.002 |
*Adjusted for mean arterial blood pressure, congestive heart failure, peripheral vascular disease, diabetes mellitus, dementia, cerebrovascular accident, chronic liver disease, Age and Gender
ACE/ARBs—angiotensin-converting-enzyme inhibitor or angiotensin receptor blockers
Factors associated with change in creatinine levels (creatinine levels at the hospitalization compared to the baseline mean creatinine form the preceding year).
| Parameter | Odds Ratio | 95% Confidence Interval | ||
|---|---|---|---|---|
| Lower | Upper | p-value | ||
| Intercept | 1.009 | 0.992 | 1.025 | 0.280 |
| Change in temperature (5 C°) | 1.012 | 1.009 | 1.015 | <0.001 |
| CKD 3–5 | 1.000 | 0.987 | 1.012 | 0.944 |
| Age >75 | 1.008 | 0.999 | 1.017 | 0.063 |
| Any infection | 1.045 | 1.034 | 1.056 | <0.001 |
| ACE/ARBs | 1.008 | 0.997 | 1.018 | 0.143 |
| Thiazide | 1.016 | 1.000 | 1.032 | 0.047 |
| Thiazide and ACE/ARBs | 1.020 | 1.006 | 1.034 | 0.004 |
ACE/ARBs—angiotensin-converting-enzyme inhibitor or angiotensin receptor blockers
Fig 2The cumulative increase in serum creatinine (mg/dL) for the addition of each clinical characteristic.
The additional p value for each parameter is presented in brackets. ACE/ARBs—angiotensin-converting-enzyme inhibitor or angiotensin receptor blockers, CKD–chronic kidney disease